<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The extent to which concordance with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treatment quality metrics varies by patient characteristics in the publicly insured is not well understood </plain></SENT>
<SENT sid="1" pm="."><plain>Our objective was to evaluate the quality of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> care for publicly insured residents of New York State (NYS) </plain></SENT>
<SENT sid="2" pm="."><plain>NYS <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry data were linked to Medicaid and Medicare claims and hospital discharge data </plain></SENT>
<SENT sid="3" pm="."><plain>We identified <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cases diagnosed from 2004 through 2006 and evaluated three treatment quality measures: adjuvant chemotherapy within 4 months of diagnosis for American Joint <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Committee (AJCC) stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, adjuvant radiation within 6 months of diagnosis for AJCC stage IIB or III <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, and adjuvant chemotherapy within 9 months of diagnosis for AJCC stage II-III <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Concordance with guidelines was evaluated separately for Medicaid-enrollees under age 65 years and Medicare-enrollees aged 65-79 years </plain></SENT>
<SENT sid="5" pm="."><plain>For adjuvant chemotherapy for <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, 79.4% (274/345) of the Medicaid cohort and 71.8% (585/815) of the Medicare cohort were guideline concordant </plain></SENT>
<SENT sid="6" pm="."><plain>For adjuvant radiation for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, 72.3% (125/173) of the Medicaid cohort and 66.9% (206/308) of the Medicare cohort were concordant </plain></SENT>
<SENT sid="7" pm="."><plain>For adjuvant chemotherapy for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, 89.5% (238/266) of the Medicaid cohort and 76.0% (392/516) of the Medicare cohort were concordant </plain></SENT>
<SENT sid="8" pm="."><plain>Younger age was associated with higher adjusted odds of concordance for <z:hpo ids='HP_0000001'>all</z:hpo> three measures in the Medicare cohort </plain></SENT>
<SENT sid="9" pm="."><plain>Racial differences were not evident in either cohort </plain></SENT>
<SENT sid="10" pm="."><plain>There is room for improvement in concordance with accepted metrics of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> care quality </plain></SENT>
<SENT sid="11" pm="."><plain>Feedback about performance may assist in targeting efforts to improve care </plain></SENT>
</text></document>